Johnson & Johnson Profit Margin 2011-2025 | JNJ
Current and historical gross margin, operating margin and net profit margin for Johnson & Johnson (JNJ) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Johnson & Johnson net profit margin as of September 30, 2025 is 27.26%.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $468.343B | $88.821B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $962.193B | 46.28 |
| AbbVie (ABBV) | United States | $412.207B | 24.68 |
| Roche Holding AG (RHHBY) | Switzerland | $289.080B | 0.00 |
| Novartis AG (NVS) | Switzerland | $279.452B | 14.81 |
| Merck (MRK) | United States | $226.981B | 10.57 |
| Novo Nordisk (NVO) | Denmark | $224.411B | 13.16 |
| Pfizer (PFE) | United States | $147.089B | 8.08 |
| Sanofi (SNY) | France | $127.490B | 12.24 |
| Bayer (BAYRY) | Germany | $32.892B | 5.77 |
| Innoviva (INVA) | United States | $1.404B | 8.34 |